Generic Pharmaceuticals Stocks Q4 Highlights: Amphastar Pharmaceuticals (NASDAQ:AMPH)

Looking back on generic pharmaceuticals stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Amphastar Pharmaceuticals (NASDAQ:AMPH) and its peers.

The generic pharmaceutical industry operates on a volume-driven, low-cost business model, producing bioequivalent versions of branded drugs once their patents expire. These companies benefit from consistent demand for affordable medications, as they are critical to reducing healthcare costs. Generics typically face lower R&D expenses and shorter regulatory approval timelines compared to branded drug makers, enabling cost efficiencies. However, the industry is highly competitive, with intense pricing pressures, thin margins, and frequent legal challenges from branded pharmaceutical companies over patent disputes. Looking ahead, the industry is supported by tailwinds such as the role of AI in streamlining drug development (reverse engineering complex formulations) and manufacturing efficiency (optimize processes and remove inefficiencies). Governments and insurers' focus on reducing drug costs can also boost generics' adoption. However, headwinds include escalating pricing pressure from large buyers like pharmacy chains and healthcare distributors as well as evolving regulatory hurdles.

The 4 generic pharmaceuticals stocks we track reported a mixed Q4. As a group, revenues beat analysts’ consensus estimates by 2.4%.

Amidst this news, share prices of the companies have had a rough stretch. On average, they are down 10.3% since the latest earnings results.

Weakest Q4: Amphastar Pharmaceuticals (NASDAQ:AMPH)

Founded in 1996 and known for its expertise in complex drug formulations, Amphastar Pharmaceuticals (NASDAQ:AMPH) develops and manufactures technically challenging injectable and inhalation medications, including both generic and proprietary pharmaceutical products.

Amphastar Pharmaceuticals reported revenues of $183.1 million, down 1.8% year on year. This print fell short of analysts’ expectations by 2.5%. Overall, it was a disappointing quarter for the company with a significant miss of analysts’ revenue estimates and a significant miss of analysts’ EPS estimates.

Amphastar Pharmaceuticals delivered the weakest performance against analyst estimates and slowest revenue growth of the whole group. Unsurprisingly, the stock is down 23.7% since reporting and currently trades at $20.20.

Read our full report on Amphastar Pharmaceuticals here, it’s free.

Best Q4: ANI Pharmaceuticals (NASDAQ:ANIP)

With a diverse portfolio of 116 pharmaceutical products and a growing rare disease platform, ANI Pharmaceuticals (NASDAQ:ANIP) develops, manufactures, and markets branded and generic prescription pharmaceuticals, with a focus on rare disease treatments.

ANI Pharmaceuticals reported revenues of $247.1 million, up 29.6% year on year, outperforming analysts’ expectations by 6.9%. The business had a stunning quarter with a solid beat of analysts’ revenue estimates and an impressive beat of analysts’ full-year EPS guidance estimates.

ANI Pharmaceuticals delivered the biggest analyst estimates beat and fastest revenue growth among its peers. However, the results were likely priced into the stock as it’s traded sideways since reporting. Shares currently sit at $76.65.

Is now the time to buy ANI Pharmaceuticals? Access our full analysis of the earnings results here, it’s free.

Amneal (NASDAQ:AMRX)

Founded in 2002 and growing into one of America's largest generic drug producers, Amneal Pharmaceuticals (NASDAQ:AMRX) develops, manufactures, and distributes generic medicines, specialty branded drugs, biosimilars, and injectable products for the U.S. healthcare market.

Amneal reported revenues of $814.3 million, up 11.5% year on year, exceeding analysts’ expectations by 0.9%. Still, it was a mixed quarter as it posted full-year revenue guidance missing analysts’ expectations significantly.

As expected, the stock is down 8.5% since the results and currently trades at $13.26.

Read our full analysis of Amneal’s results here.

Viatris (NASDAQ:VTRS)

Created through the 2020 merger of Mylan and Pfizer's Upjohn division, Viatris (NASDAQ:VTRS) is a healthcare company that develops, manufactures, and distributes branded and generic medicines across more than 165 countries worldwide.

Viatris reported revenues of $3.70 billion, up 5% year on year. This number topped analysts’ expectations by 4.5%. It was a strong quarter as it also logged an impressive beat of analysts’ revenue estimates and full-year revenue guidance exceeding analysts’ expectations.

Viatris scored the highest full-year guidance raise among its peers. The stock is down 8.4% since reporting and currently trades at $14.73.

Read our full, actionable report on Viatris here, it’s free.

Want to invest in winners with rock-solid fundamentals? Check out our Top 5 Quality Compounder Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate.